WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) on Tuesday reported global net trade sales of $3.964 billion for DARZALEX (daratumumab) in the first quarter of 2026, according to company announcements.
The cancer therapy, marketed by Johnson & Johnson, demonstrated robust performance across major markets. United States sales reached $2.208 billion, while international markets generated $1.756 billion in revenue.
Genmab earns royalties on worldwide DARZALEX sales through its licensing agreement with Johnson & Johnson. The therapy treats multiple myeloma and remains a key revenue driver for the company. DARZALEX is available in both intravenous and subcutaneous formulations, providing treatment options for patients with this serious blood cancer.
GMAB is currently trading at $29.10, up $0.90 or 3.21 percent on the Nasdaq.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
